Clinical Trial Update: Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating masitinib in combination with FOLFIRI as second-line therapy for metastatic colorectal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Folinic acid (folinic acid)
• Irinotecan (Irinotecan)
• Masitinib (masitinib)

Snippet

Sponsor: AB Science | Conditions: Metastatic Colorectal Cancer | Phase 3 | Status: TERMINATED